Literature DB >> 29099495

A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia.

H Sakai1,2, N Hosono1, H Nakazawa2, B Przychodzen1, C Polprasert1, H E Carraway1, M A Sekeres1,3, T Radivoyevitch1, K Yoshida4,5, M Sanada4,5,6, T Yoshizato4,5, K Kataoka4,5, M M Nakagawa4, H Ueno4, Y Nannya4, A Kon4,5, Y Shiozawa4,5, J Takeda4, Y Shiraishi7, K Chiba7, S Miyano7, J Singh8, R A Padgett8, S Ogawa4,5, J P Maciejewski1, H Makishima1,2,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29099495      PMCID: PMC8694071          DOI: 10.1038/leu.2017.319

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  The SWI/SNF complex--chromatin and cancer.

Authors:  Charles W M Roberts; Stuart H Orkin
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

2.  A landscape of driver mutations in melanoma.

Authors:  Eran Hodis; Ian R Watson; Gregory V Kryukov; Stefan T Arold; Marcin Imielinski; Jean-Philippe Theurillat; Elizabeth Nickerson; Daniel Auclair; Liren Li; Chelsea Place; Daniel Dicara; Alex H Ramos; Michael S Lawrence; Kristian Cibulskis; Andrey Sivachenko; Douglas Voet; Gordon Saksena; Nicolas Stransky; Robert C Onofrio; Wendy Winckler; Kristin Ardlie; Nikhil Wagle; Jennifer Wargo; Kelly Chong; Donald L Morton; Katherine Stemke-Hale; Guo Chen; Michael Noble; Matthew Meyerson; John E Ladbury; Michael A Davies; Jeffrey E Gershenwald; Stephan N Wagner; Dave S B Hoon; Dirk Schadendorf; Eric S Lander; Stacey B Gabriel; Gad Getz; Levi A Garraway; Lynda Chin
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

Review 3.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

4.  Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing.

Authors:  Rohit Mehra; Pankaj Vats; Shanker Kalyana-Sundaram; Aaron M Udager; Michael Roh; Ajjai Alva; Jincheng Pan; Robert J Lonigro; Javed Siddiqui; Alon Weizer; Cheryl Lee; Xuhong Cao; Yi-Mi Wu; Dan R Robinson; Saravana M Dhanasekaran; Arul M Chinnaiyan
Journal:  Am J Pathol       Date:  2014-01-03       Impact factor: 4.307

5.  Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.

Authors:  Meng Li; Hong Zhao; Xiaosong Zhang; Laura D Wood; Robert A Anders; Michael A Choti; Timothy M Pawlik; Hubert D Daniel; Rajesh Kannangai; G Johan A Offerhaus; Victor E Velculescu; Linfang Wang; Shibin Zhou; Bert Vogelstein; Ralph H Hruban; Nick Papadopoulos; Jianqiang Cai; Michael S Torbenson; Kenneth W Kinzler
Journal:  Nat Genet       Date:  2011-08-07       Impact factor: 38.330

6.  Dynamics of clonal evolution in myelodysplastic syndromes.

Authors:  Hideki Makishima; Tetsuichi Yoshizato; Kenichi Yoshida; Mikkael A Sekeres; Tomas Radivoyevitch; Hiromichi Suzuki; Bartlomiej Przychodzen; Yasunobu Nagata; Manja Meggendorfer; Masashi Sanada; Yusuke Okuno; Cassandra Hirsch; Teodora Kuzmanovic; Yusuke Sato; Aiko Sato-Otsubo; Thomas LaFramboise; Naoko Hosono; Yuichi Shiraishi; Kenichi Chiba; Claudia Haferlach; Wolfgang Kern; Hiroko Tanaka; Yusuke Shiozawa; Inés Gómez-Seguí; Holleh D Husseinzadeh; Swapna Thota; Kathryn M Guinta; Brittney Dienes; Tsuyoshi Nakamaki; Shuichi Miyawaki; Yogen Saunthararajah; Shigeru Chiba; Satoru Miyano; Lee-Yung Shih; Torsten Haferlach; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Genet       Date:  2016-12-19       Impact factor: 38.330

7.  Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.

Authors:  Gilles Manceau; Eric Letouzé; Cécile Guichard; Audrey Didelot; Aurelie Cazes; Hélène Corté; Elizabeth Fabre; Karine Pallier; Sandrine Imbeaud; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Pierre Laurent-Puig; Hélène Blons
Journal:  Int J Cancer       Date:  2012-11-20       Impact factor: 7.396

8.  Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance.

Authors:  Manuel Buscarlet; Veneta Krasteva; Lena Ho; Camille Simon; Josée Hébert; Brian Wilhelm; Gerald R Crabtree; Guy Sauvageau; Pierre Thibault; Julie A Lessard
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

9.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

10.  Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.

Authors:  V Madan; P Shyamsunder; L Han; A Mayakonda; Y Nagata; J Sundaresan; D Kanojia; K Yoshida; S Ganesan; N Hattori; N Fulton; K-T Tan; T Alpermann; M-C Kuo; S Rostami; J Matthews; M Sanada; L-Z Liu; Y Shiraishi; S Miyano; E Chendamarai; H-A Hou; G Malnassy; T Ma; M Garg; L-W Ding; Q-Y Sun; W Chien; T Ikezoe; M Lill; A Biondi; R A Larson; B L Powell; M Lübbert; W J Chng; H-F Tien; M Heuser; A Ganser; M Koren-Michowitz; S M Kornblau; H M Kantarjian; D Nowak; W-K Hofmann; H Yang; W Stock; A Ghavamzadeh; K Alimoghaddam; T Haferlach; S Ogawa; L-Y Shih; V Mathews; H P Koeffler
Journal:  Leukemia       Date:  2016-04-11       Impact factor: 11.528

View more
  4 in total

Review 1.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

2.  The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis.

Authors:  Lulu Liu; Xiaoling Wan; Peipei Zhou; Xiaoyuan Zhou; Wei Zhang; Xinhui Hui; Xiujie Yuan; Xiaodan Ding; Ruihong Zhu; Guangxun Meng; Hui Xiao; Feng Ma; He Huang; Xianmin Song; Bin Zhou; Sidong Xiong; Yan Zhang
Journal:  J Hematol Oncol       Date:  2018-02-26       Impact factor: 17.388

3.  Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.

Authors:  JinJuan Yao; Lianrong Xu; Umut Aypar; Howard J Meyerson; Dory Londono; Qi Gao; Jeeyeon Baik; James Dietz; Ryma Benayed; Allison Sigler; Mariko Yabe; Ahmet Dogan; Maria E Arcila; Mikhail Roshal; Yanming Zhang; Michael J Mauro; Wenbin Xiao
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

4.  Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.

Authors:  Emiliano Fabiani; Laura Cicconi; Anna Maria Nardozza; Antonio Cristiano; Marianna Rossi; Tiziana Ottone; Giulia Falconi; Mariadomenica Divona; Anna Maria Testi; Ombretta Annibali; Roberto Castelli; Vladimir Lazarevic; Eduardo Rego; Pau Montesinos; Jordi Esteve; Adriano Venditti; Matteo Della Porta; William Arcese; Francesco Lo-Coco; Maria Teresa Voso
Journal:  Cancer Med       Date:  2021-05-27       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.